SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
📖

CSF Dynamics and Glymphatic Therapy in CBS/PSP

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-csf-glymphatic-therapy
Related Entities
therapeutics-csf-glymphatic-therapy-cbs-psp
Metadata
slugtherapeutics-csf-glymphatic-therapy-cbs-psp
entity_typetherapeutic
kg_node_idNone
Linked Artifacts (668)
mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%
related🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%
mentions🔬Neuroinflammation and microglial priming in early Alzheimer&75%
mentions🧫CSF iron content analysis in RLS patients versus controls70%
mentions🧫iPSC-derived endothelial cell iron uptake with RLS CSF expos70%
mentions🧫Proposed experiment from debate on Perivascular spaces and g70%
mentions🧫s:** - Test tau spreading in AQP4 knockout vs wild-type mice70%
mentions🧫FLS Stimulation and Transcriptomic Analysis70%
mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 70%
mentions🧫4R-Tau Targeting Therapies for PSP and CBS70%
mentions🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi70%
mentions🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back70%
mentions🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio70%
mentions🧫Computational Modeling of Alpha-Synuclein Propagation in PD70%
mentions🧫Alpha-Synuclein Seed Amplification Assay Validation70%
mentions🧫ALS Progression Rate Heterogeneity — mechanism and biomarker70%
mentions🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk70%
mentions🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti70%
mentions🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?70%
mentions🧫Anti-Tau Immunotherapy Dosing Optimization70%
mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
mentions🧫Antiviral Therapy Trial for Parkinson's Disease70%
mentions🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&70%
mentions🧫Experiment: Autoimmune Hypothesis Testing in AD70%
mentions🧫Autophagy Enhancement Drug Screening for Neurodegeneration70%
mentions🧫Axonal Transport Dysfunction Validation in Parkinson's 70%
mentions🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#70%
mentions🧫Blood-Based Biomarker Panel for Early AD Detection70%
mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring70%
mentions🧫tACS Connectivity Trial in Early Alzheimer's70%
mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD70%
mentions🧫Brainstem Circuit Modulation for PSP70%
mentions🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study70%
mentions🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 70%
mentions🧫cGAS-STING Pathway Validation Study in Parkinson's Dise70%
mentions🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 70%
mentions🧫Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Tr70%
mentions🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M70%
mentions🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera70%
mentions🧫DLB Cognitive Fluctuation Mechanism Experiment70%
mentions🧫Genetic Risk Modifiers in DLB Phenotype70%
mentions🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras70%
mentions🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#70%
mentions🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera70%
mentions🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%
mentions🧫Epigenetic Clocks in Neurodegeneration — Causal Drivers or P70%
mentions🧫Exercise-BDNF-Mitophagy Biomarker Study in PD70%
mentions🧫Ferroptosis Validation in Parkinson's Disease70%
mentions🧫Frontal and Temporal Lobe Selective Vulnerability in FTD — M70%
mentions🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud70%
mentions🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation70%
mentions🧫Gap Junction Dysfunction Validation in Parkinson's Dise70%
mentions🧫GLP-1 Agonist Neuroprotection Mechanism in PD70%
mentions🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin70%
mentions🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%
mentions🧫Iron Dyshomeostasis in MSA Pathogenesis Experiment70%
mentions🧫Levodopa-Induced Dyskinesias Mechanism — Experiment Design70%
mentions🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%
mentions🧫Cytochrome Therapeutics70%
mentions🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson70%
mentions🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne70%
mentions🧫Macroautophagy Dysfunction in PD - Experiment Design70%
mentions🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise70%
mentions🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 70%
mentions🧫Microglial Contributions to Huntington's Disease Pathog70%
mentions🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis70%
mentions🧫Mixed Pathology Effects on Parkinson's Disease Progress70%
mentions🧫N-of-1 Clinical Trial Design for CBS/PSP70%
mentions🧫Neural Stem Cell Therapy for Alzheimer's Disease70%
mentions🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise70%
mentions🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper70%
mentions🧫Non-Motor Symptom Progression in Parkinson's Disease — 70%
mentions🧫Normal Aging to Alzheimer's Disease Transition Trigger 70%
mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 70%
mentions🧫NPH Glymphatic System Interaction Experiment70%
mentions🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%
mentions🧫Parkinson's Disease Subtype Classification — Precision 70%
mentions🧫Peroxisomal Dysfunction Validation in Parkinson's Disea70%
mentions🧫Peroxisome Dysfunction Validation in Parkinson's Diseas70%
mentions🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers70%
mentions🧫Presymptomatic GRN Carrier Intervention Timing — Biomarker-G70%
mentions🧫Pre-Symptomatic Detection and Intervention Timing in Genetic70%
mentions🧫Prion Strain Diversity and Selective Vulnerability in CJD70%
mentions🧫Prodromal Parkinson's Disease Biomarker Development — E70%
mentions🧫Progranulin Replacement Therapy for FTD — Vector Development70%
mentions🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD70%
mentions🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%
mentions🧫PSP and CBS Biomarker Validation Study70%
mentions🧫Purinergic Signaling Dysfunction Validation in Parkinson70%
mentions🧫Regulated Necrosis Validation Study in Parkinson's Dise70%
mentions🧫Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel70%
mentions🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease70%
mentions🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#70%
mentions🧫Sex Differences in Alzheimer's Disease — mechanisms and70%
mentions🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D70%
mentions🧫Sleep and Circadian Dysfunction as Driver of Neurodegenerati70%
mentions🧫Sleep Disruption and Alzheimer's Disease — mechanism an70%
mentions🧫Sleep and Respiratory Network Interaction in ALS — Experimen70%
mentions🧫Stress Granule Dysfunction Validation in Parkinson's Di70%
mentions🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo70%
mentions🧫Tau Propagation Causality Test — Does Tau Spread Drive Neuro70%
mentions🧫Traumatic Brain Injury and Alzheimer's Disease Relation70%
mentions🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal70%
mentions🧫TDP-43 PET Ligand Development for FTD and ALS70%
mentions🧫Tau ASO Therapy70%
mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia70%
mentions🧫Vascular Contribution to Alzheimer's Disease — Beyond A70%
mentions🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol70%
mentions🧫Viral Infections and Alzheimer's Disease — causal mecha70%
mentions🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des70%
mentions🧫Wilson Disease Neurodegeneration: Mechanism and Therapeutic 70%
mentions🧪Purinergic Signaling Polarization Control70%
mentions🧪Lipid Droplet Dynamics as Phenotype Switches70%
mentions🧪Mechanosensitive Ion Channel Reprogramming70%
related🧫CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫Brainstem Circuit Modulation for PSP70%
related🧫Tau Pathology Initiation Zone Identification70%
related🧫Tau Spreading Network Mapping via Spatial Transcriptomics in70%
related🧫CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi70%
related🧫N-of-1 Clinical Trial Design for CBS/PSP70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫4R-Tau Targeting Therapies for PSP and CBS70%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
related🧫Brainstem Circuit Modulation for PSP70%
related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%
related🧫PSP and CBS Biomarker Validation Study70%
related🧫Tau Pathology Initiation Zone Identification70%
related🧫Tau Spreading Network Mapping via Spatial Transcriptomics in70%
mentions🧪Aquaporin-4 Polarization Rescue67%
related🔬Neuroinflammation and microglial priming in early Alzheimer&67%
mentions🧪SASP-Driven Aquaporin-4 Dysregulation67%
mentions🧪Glymphatic System-Enhanced Antibody Clearance Reversal67%
related🧫CSF iron content analysis in RLS patients versus controls63%
related🧫iPSC-derived endothelial cell iron uptake with RLS CSF expos63%
related🧫Proposed experiment from debate on Perivascular spaces and g63%
related🧫s:** - Test tau spreading in AQP4 knockout vs wild-type mice63%
related🧫FLS Stimulation and Transcriptomic Analysis63%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 63%
related🧫4R-Tau Targeting Therapies for PSP and CBS63%
related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi63%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back63%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio63%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD63%
related🧫Alpha-Synuclein Seed Amplification Assay Validation63%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker63%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk63%
related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti63%
related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?63%
related🧫Anti-Tau Immunotherapy Dosing Optimization63%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri63%
related🧫Antiviral Therapy Trial for Parkinson's Disease63%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&63%
related🧫Experiment: Autoimmune Hypothesis Testing in AD63%
related🧫Autophagy Enhancement Drug Screening for Neurodegeneration63%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 63%
related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#63%
related🧫Blood-Based Biomarker Panel for Early AD Detection63%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring63%
related🧫tACS Connectivity Trial in Early Alzheimer's63%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD63%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study63%
related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 63%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise63%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 63%
related🧫Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Tr63%
related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M63%
related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera63%
related🧫DLB Cognitive Fluctuation Mechanism Experiment63%
related🧫Genetic Risk Modifiers in DLB Phenotype63%
related🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras63%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#63%
related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera63%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#63%
related🧫Epigenetic Clocks in Neurodegeneration — Causal Drivers or P63%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD63%
related🧫Ferroptosis Validation in Parkinson's Disease63%
related🧫Frontal and Temporal Lobe Selective Vulnerability in FTD — M63%
related🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud63%
related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation63%
related🧫Gap Junction Dysfunction Validation in Parkinson's Dise63%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD63%
related🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin63%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&63%
related🧫Iron Dyshomeostasis in MSA Pathogenesis Experiment63%
related🧫Levodopa-Induced Dyskinesias Mechanism — Experiment Design63%
related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre63%
related🧫Cytochrome Therapeutics63%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson63%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne63%
related🧫Macroautophagy Dysfunction in PD - Experiment Design63%
related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise63%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 63%
related🧫Microglial Contributions to Huntington's Disease Pathog63%
related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis63%
related🧫Mixed Pathology Effects on Parkinson's Disease Progress63%
related🧫N-of-1 Clinical Trial Design for CBS/PSP63%
related🧫Neural Stem Cell Therapy for Alzheimer's Disease63%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise63%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper63%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 63%
related🧫Normal Aging to Alzheimer's Disease Transition Trigger 63%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 63%
related🧫NPH Glymphatic System Interaction Experiment63%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#63%
related🧫Parkinson's Disease Subtype Classification — Precision 63%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea63%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas63%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers63%
related🧫Presymptomatic GRN Carrier Intervention Timing — Biomarker-G63%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic63%
related🧫Prion Strain Diversity and Selective Vulnerability in CJD63%
related🧫Prodromal Parkinson's Disease Biomarker Development — E63%
related🧫Progranulin Replacement Therapy for FTD — Vector Development63%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD63%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin63%
related🧫PSP and CBS Biomarker Validation Study63%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson63%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise63%
related🧫Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel63%
related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease63%
related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#63%
related🧫Sex Differences in Alzheimer's Disease — mechanisms and63%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D63%
related🧫Sleep and Circadian Dysfunction as Driver of Neurodegenerati63%
related🧫Sleep Disruption and Alzheimer's Disease — mechanism an63%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen63%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di63%
related🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo63%
related🧫Tau Propagation Causality Test — Does Tau Spread Drive Neuro63%
related🧫Traumatic Brain Injury and Alzheimer's Disease Relation63%
related🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal63%
related🧫TDP-43 PET Ligand Development for FTD and ALS63%
related🧫Tau ASO Therapy63%
related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia63%
related🧫Vascular Contribution to Alzheimer's Disease — Beyond A63%
related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol63%
related🧫Viral Infections and Alzheimer's Disease — causal mecha63%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des63%
related🧫Wilson Disease Neurodegeneration: Mechanism and Therapeutic 63%
related🧪Purinergic Signaling Polarization Control63%
related🧪Lipid Droplet Dynamics as Phenotype Switches63%
related🧪Mechanosensitive Ion Channel Reprogramming63%
related🧪Aquaporin-4 Polarization Rescue60%
related🧪SASP-Driven Aquaporin-4 Dysregulation60%
related🧪Glymphatic System-Enhanced Antibody Clearance Reversal60%
mentions🔬Extracellular vesicle biomarkers for early AD detection60%
mentions🔬What are the mechanisms underlying 4r-tau strain-specific sp60%
mentions🔬PSP and CBD both involve 4R-tau but produce distinct neuropa60%
related🔬Extracellular vesicle biomarkers for early AD detection54%
related🔬What are the mechanisms underlying 4r-tau strain-specific sp54%
related🔬PSP and CBD both involve 4R-tau but produce distinct neuropa54%
mentions🧪Lysosomal Positioning Dynamics Modulation50%
mentions🧪Circadian Glymphatic Entrainment via Targeted Orexin Recepto50%
mentions🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)50%
mentions🧪Ganglioside Rebalancing Therapy50%
mentions🧪Arginine Methylation Enhancement Therapy50%
mentions🧪Complement C1q Mimetic Decoy Therapy50%
mentions🧪CYP46A1 Overexpression Gene Therapy50%
mentions🧪SIRT6-NAD+ Axis Enhancement Therapy50%
mentions🧪PARP1 Inhibition Therapy50%
mentions🧪Hypocretin-Neurogenesis Coupling Therapy50%
mentions🧪Orexin-Microglia Modulation Therapy50%
mentions🧪Lysosomal Calcium Channel Modulation Therapy50%
mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%
mentions🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th50%
mentions🧪Glial Glycocalyx Remodeling Therapy50%
mentions🧪R-Loop Resolution Enhancement Therapy50%
mentions🧪HCN1-Mediated Resonance Frequency Stabilization Therapy50%
mentions🧪TET2-Mediated Demethylation Rejuvenation Therapy50%
mentions🧪Selective Acid Sphingomyelinase Modulation Therapy50%
mentions🧪Purinergic P2Y12 Inverse Agonist Therapy50%
mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy50%
mentions🧪Near-infrared light therapy stimulates COX4-dependent mitoch50%
related🔬What are the mechanisms underlying 4r-tau strain-specific sp50%
related🔬What are the mechanisms underlying tdp-43 phase separation t50%
related🔬What are the mechanisms underlying astrocyte reactivity subt50%
related🔬What are the mechanisms underlying blood-brain barrier trans50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%
related🔬What are the mechanisms underlying senolytic therapy for age50%
related🔬What are the mechanisms underlying neuroinflammation resolut50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬Investigate how lipid raft composition (cholesterol metaboli50%
related🔬What are the mechanisms underlying sleep disruption as cause50%
related🔬What are the mechanisms underlying rna binding protein dysre50%
related🔬What are the mechanisms underlying synaptic pruning by micro50%
related🔬What are the mechanisms underlying mitochondrial transfer be50%
related🔬What are the mechanisms underlying epigenetic clocks and bio50%
related🔬What are the mechanisms underlying perivascular spaces and g50%
related🔬Analyze circuit-level changes in neurodegeneration using All50%
related🔬What are the mechanisms underlying selective vulnerability o50%
related🔬What are the mechanisms underlying tdp-43 phase separation t50%
related🔬What are the mechanisms underlying astrocyte reactivity subt50%
related🔬What are the mechanisms underlying blood-brain barrier trans50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%
related🔬What are the mechanisms underlying senolytic therapy for age50%
related🔬What are the mechanisms underlying neuroinflammation resolut50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬Investigate how lipid raft composition (cholesterol metaboli50%
related🔬What are the mechanisms underlying sleep disruption as cause50%
related🔬What are the mechanisms underlying rna binding protein dysre50%
related🔬What are the mechanisms underlying synaptic pruning by micro50%
related🔬What are the mechanisms underlying mitochondrial transfer be50%
related🔬What are the mechanisms underlying epigenetic clocks and bio50%
related🔬What are the mechanisms underlying perivascular spaces and g50%
related🔬Analyze circuit-level changes in neurodegeneration using All50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Senescent cell clearance as neurodegeneration therapy50%
related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%
related🔬Perivascular spaces and glymphatic clearance failure in AD50%
related🔬What are the mechanisms underlying protein aggregation cross50%
related🔬What are the mechanisms underlying mechanistic role of apoe 50%
see_also📖Cell-Free DNA Biomarkers in Neurodegeneration50%
see_also📖Exosomal Biomarkers in Neurodegeneration50%
see_also📖Exosomal miR-155 in Neurodegeneration50%
see_also📖IL-6 (Interleukin-6) in Neurodegeneration50%
see_also📖Liquid Biopsy in Neurodegeneration50%
see_also📖Metabolomic Biomarkers in Neurodegeneration50%
see_also📖Neuroimaging Biomarkers for Neurodegeneration50%
see_also📖p-Tau Biomarker in Immunoglobulin Light Chain and Transthyre50%
see_also📖Synaptic Biomarkers in Neurodegeneration50%
see_also📖BEACoN Study - Biomarker Exploration in Aging, Cognition and50%
see_also📖Digital Therapeutic Platform for Swallowing and Drooling Pro50%
see_also📖Utilisation of Health Services and Quality of Life in Atypic50%
see_also📖Phase 3 Study to Compare the Efficacy and Safety of Masitini50%
see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 50%
see_also📖Long-term Effects of Hearing Intervention on Brain Health in50%
see_also📖A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial50%
see_also📖A 6-month & 18-month Prospective, Randomized, Placebo-co50%
see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St50%
see_also📖Olfactory Mucosa, Blood and Urine for Identification of Earl50%
see_also📖PCDH19-Related Epilepsy (EFMR) — Preclinical Gene Therapy Pr50%
see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime50%
see_also📖Swedish BioFINDER 2 Study: Biomarkers and Neurodegeneration 50%
see_also📖Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pi50%
see_also📖Beta-Propeller Protein-Associated Neurodegeneration (BPAN)50%
see_also📖CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subc50%
see_also📖China Neurodegeneration Epidemiology50%
see_also📖DALY Methodology — Neurodegeneration50%
see_also📖Disease Progression & Staging in Neurodegeneration50%
see_also📖Economic Burden — Neurodegeneration50%
see_also📖European Neurodegeneration Epidemiology50%
see_also📖Familial vs Sporadic Neurodegeneration Comparison50%
see_also📖Global Neurodegeneration Epidemiology50%
see_also📖Hereditary Sensory and Autonomic Neuropathy (HSAN)50%
see_also📖India Neurodegeneration Epidemiology50%
see_also📖Japan Neurodegeneration Epidemiology50%
see_also📖Manganese-Related Neurodegeneration (Manganism)50%
see_also📖MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acid50%
see_also📖Mirror Therapy and Sensory Re-education in Corticobasal Synd50%
see_also📖mitochondrial-dysfunction-neurodegeneration-comparison50%
see_also📖Mitochondrial Diseases and Neurodegeneration Comparison Matr50%
see_also📖Mitochondrial Membrane Protein-Associated Neurodegeneration 50%
see_also📖Neurodegeneration with Brain Iron Accumulation (NBIA)50%
see_also📖Potential Impact Measures — Neurodegeneration50%
see_also📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)50%
see_also📖Physical and Occupational Therapy in Corticobasal Syndrome50%
see_also📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)50%
see_also📖PLA2G6-Associated Neurodegeneration (PLAN)50%
see_also📖Healthcare Economics and Cost of Illness in Progressive Supr50%
see_also📖PSP and Idiopathic Normal Pressure Hydrocephalus: Clinical O50%
see_also📖Sleep Disorders in Neurodegeneration50%
see_also📖Speech Therapy and Communication Aids in Corticobasal Syndro50%
see_also📖US Neurodegeneration Epidemiology50%
see_also📖Extracellular Vesicle and Tunneling Nanotube-Mediated Spread50%
see_also📖acetylcholine-signaling-neurodegeneration50%
see_also📖Advanced Glycation End Products in Neurodegeneration50%
see_also📖Advanced In Vitro Models for Neurodegeneration — Organoids, 50%
see_also📖Amylin Signaling in Neurodegeneration50%
see_also📖Antibody Therapy in Neurodegeneration50%
see_also📖Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration50%
see_also📖Autosis Pathway in Neurodegeneration50%
see_also📖Axon Guidance Pathways in Neurodegeneration50%
see_also📖Basal Ganglia Circuit Dysfunction in Neurodegeneration50%
see_also📖Blood-Brain Barrier Dysfunction and Therapeutic Delivery for50%
see_also📖becn1-autophagy-initiation-neurodegeneration-causal-chain50%
see_also📖Braak Staging and Tau Propagation Pathway50%
see_also📖CaMKII Signaling Pathway in Neurodegeneration50%
see_also📖Carbonic Anhydrase Modulator Therapy in Neurodegeneration50%
see_also📖Multimodal Diagnostic Algorithm for CBS and PSP50%
see_also📖CBS/PSP Panxoneopathy and Membrane Biology50%
see_also📖Cerebral Amyloid Angiopathy in Neurodegeneration50%
see_also📖Cerebral Amyloid Angiopathy Pathway in Neurodegeneration50%
see_also📖Cholinergic System Dysfunction in Neurodegeneration50%
see_also📖Chrononutrition and Time-Restricted Eating in Neurodegenerat50%
see_also📖Neural Circuits in Neurodegeneration50%
see_also📖Cognitive Reserve and Resilience in Neurodegeneration50%
see_also📖Computational Disease Models for Neurodegeneration50%
see_also📖Convergent Pathways in Neurodegeneration50%
see_also📖Copper Homeostasis in Neurodegeneration50%
see_also📖COVID-19 Neurodegeneration Mechanism50%
see_also📖Diffusion MRI (DTI) in Neurodegeneration50%
see_also📖Digital Phenotyping in Neurodegeneration50%
see_also📖Down Syndrome Neurodegeneration Pathway50%
see_also📖Dystrophic Neurites in Neurodegeneration50%
see_also📖Endocannabinoid System in Neurodegeneration50%
see_also📖Endosomal-Lysosomal Pathway in Neurodegeneration50%
see_also📖Endosomal Sorting Defects in Neurodegeneration50%
see_also📖Endothelin Signaling Pathway in Neurodegeneration50%
see_also📖epigenetics-neurodegeneration50%
see_also📖ESCRT-III Inhibition by Alpha-Synuclein in Neurodegeneration50%
see_also📖FA2H-Associated Neurodegeneration Pathway50%
see_also📖Farnesoid X Receptor (FXR) Signaling in Neurodegeneration50%
see_also📖Galectin-3 Mechanism in Neurodegeneration50%
see_also📖Gangliosides in Neurodegeneration50%
see_also📖GDF15/GDF11 Signaling in Neurodegeneration50%
see_also📖GDNF Signaling Pathway in Neurodegeneration50%
see_also📖Geniposide for Alzheimer's disease - immune biomarker t50%
see_also📖Ghrelin Signaling Pathway in Neurodegeneration50%
see_also📖Glial Tau Pathology in PSP and CBD50%
see_also📖Glucocorticoid Signaling Pathway in Neurodegeneration50%
see_also📖Glycosylation in Neurodegeneration50%
see_also📖Glymphatic Clearance Hypothesis — Impaired Aβ and Tau Remova50%
see_also📖Glymphatic and Vascular Clearance Dysfunction in 4R-Tauopath50%
see_also📖gp130/IL-6 Family Cytokine Signaling in Neurodegeneration50%
see_also📖Hippocampal Neurogenesis in Neurodegeneration50%
see_also📖Histone Modification Pathways in Neurodegeneration50%
see_also📖HMGB1 Signaling in Neurodegeneration50%
see_also📖Homocysteine Neurotoxicity and Neurodegeneration50%
see_also📖IGF-1 Signaling Pathway in Neurodegeneration50%
see_also📖IL-1 Signaling Pathway in Neurodegeneration50%
see_also📖Integrated Stress Response in Neurodegeneration50%
see_also📖interleukin-6-signaling-neurodegeneration50%
see_also📖Intrinsic Apoptosis Pathway in Neurodegeneration50%
see_also📖Ion Channel Dysfunction in Neurodegeneration: Cross-Disease 50%
see_also📖Kidney-Brain Neurodegeneration Axis50%
see_also📖Lipid Dysregulation in Neurodegeneration50%
see_also📖Lipid Metabolism Dysregulation in Neurodegeneration50%
see_also📖Lysosomal Calcium Dysregulation in Neurodegeneration50%
see_also📖Magnetic Resonance Spectroscopy in Neurodegeneration50%
see_also📖Metal Homeostasis Dysregulation in Neurodegeneration50%
see_also📖Metal Homeostasis in Neurodegeneration50%
see_also📖Microglial Priming Pathway in Neurodegeneration50%
see_also📖MicroRNA Dysfunction in Neurodegeneration50%
see_also📖Mineralocorticoid Receptor Signaling in Neurodegeneration50%
see_also📖Mitochondrial Dynamics Pathway in Neurodegeneration50%
see_also📖Mitochondrial Fusion in Neurodegeneration50%
see_also📖Molecular Chaperones in Neurodegeneration50%
see_also📖mTOR Signaling in Neurodegeneration50%
see_also📖mTOR Signaling Pathway in Neurodegeneration50%
see_also📖Neural Circuit Disruption in Neurodegeneration50%
see_also📖Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in N50%
see_also📖Neurofilament Light Chain (NfL) Mechanism in Neurodegenerati50%
see_also📖Neuroinflammation in Parkinson's Disease Dementia and D50%
see_also📖Neuronal Hyperexcitability in Neurodegeneration50%
see_also📖Neuropil Threads in Neurodegeneration50%
see_also📖Neurotensin Signaling in Neurodegeneration50%
see_also📖Neurovascular Unit Dysfunction in Neurodegeneration50%
see_also📖NF-kB Signaling Pathway in Neurodegeneration50%
see_also📖Nitric Oxide Signaling in Neurodegeneration50%
see_also📖Noradrenergic Signaling Pathway in Neurodegeneration50%
see_also📖Neuropeptide Y Signaling in Neurodegeneration50%
see_also📖NRF2 Signaling Pathway in Neurodegeneration50%
see_also📖Nuclear Pore Complex Dysfunction in Neurodegeneration50%
see_also📖Orexin Signaling in Neurodegeneration50%
see_also📖OSK Reprogramming and Yamanaka Factors in Neurodegeneration50%
see_also📖P-Body (Processing Body) Pathway in Neurodegeneration50%
see_also📖Paranodal Dysfunction in Neurodegeneration50%
see_also📖Paraptosis in Neurodegeneration50%
see_also📖Parthanatos in Neurodegeneration50%
see_also📖Pericyte Loss in Neurodegeneration50%
see_also📖Peripheral Immune-Brain Crosstalk in Neurodegeneration50%
see_also📖PKR Pathway in Neurodegeneration50%
see_also📖PPAR Signaling Pathway in Neurodegeneration50%
see_also📖Prion Diseases in Neurodegeneration50%
see_also📖Prion-Like Spread in Neurodegeneration50%
see_also📖Prion Protein Metabolism in Neurodegeneration50%
see_also📖Progesterone Signaling Pathway in Neurodegeneration50%
see_also📖Prognostic Biomarkers in Neurodegeneration50%
see_also📖Protein Aggregation Comparison in Neurodegeneration50%
see_also📖Protein Aggregation Seeds in Neurodegeneration50%
see_also📖Protein O-GlcNAcylation Pathway in Neurodegeneration50%
see_also📖Cortical Involvement and Neurodegeneration in Progressive Su50%
see_also📖Purinergic Signaling in Neurodegeneration50%
see_also📖Quantum Biology and Coherent Energy Transfer in Neurodegener50%
see_also📖R-Loop Stress in Neurodegeneration50%
see_also📖RAN Translation in Neurodegeneration50%
see_also📖Retinal Degeneration Pathway in Neurodegeneration50%
see_also📖Ribosome Dysfunction in Neurodegeneration50%
see_also📖RNA Splicing in Neurodegeneration50%
see_also📖RNA-Targeted Therapies in Neurodegeneration50%
see_also📖Ribonuclease κ and Circular RNAs: A New Mechanism of Aging a50%
see_also📖S100 Protein Signaling Pathway in Neurodegeneration50%
see_also📖Senescent Cell Clearance in Neurodegeneration50%
see_also📖Serotonergic Dysfunction in Neurodegeneration50%
see_also📖Sex Differences in Neurodegeneration50%
see_also📖Short Chain Fatty Acids in Neurodegeneration50%
see_also📖Sigma-1 Receptor Signaling in Neurodegeneration50%
see_also📖Sirtuin-Mitochondrial Biogenesis Axis in Neurodegeneration50%
see_also📖Sleep Dysfunction in Neurodegeneration50%
see_also📖SUMOylation in Neurodegeneration50%
see_also📖synaptic-vesicle-cycling-neurodegeneration50%
see_also📖Synthetic Lethality and PARP Inhibition in Neurodegeneration50%
see_also📖Systemic Infection and Tau Pathology Acceleration50%
see_also📖T-Cell Dysfunction in Neurodegeneration50%
see_also📖Tau Seeding and Propagation Pathway50%
see_also📖Tertiary Lymphoid Organs in Neurodegeneration50%
see_also📖Therapeutic Targets in Neurodegeneration50%
see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration50%
see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration50%
see_also📖ubiquitin-proteasome-dysfunction-neurodegeneration50%
see_also📖Ubiquitin-Proteasome System Dysfunction in Neurodegeneration50%
see_also📖Vagus Nerve Pathway in Neurodegeneration50%
see_also📖VEGF Signaling and Cerebral Angiogenesis in Neurodegeneratio50%
see_also📖vip-vasoactive-intestinal-peptide-signaling-neurodegeneratio50%
see_also📖WNK1-Bilirubin Signaling in Neuroinflammation and Neurodegen50%
see_also📖Wnt/β-Catenin Signaling Pathway in Neurodegeneration50%
see_also📖ALS Therapeutic Landscape — Programs by Phase and Modality50%
see_also📖AAIC 2026: Tau-PET Imaging and Fluid Biomarker Integration45%
see_also📖Alpha-Synuclein PET Imaging and Biomarker Advances45%
see_also📖Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)45%
see_also📖Imaging Biomarkers for Corticobasal Syndrome and Progressive45%
see_also📖Multi-Analyte Biomarker Panel for Parkinson's Disease D45%
see_also📖NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease45%
see_also📖Polygenic Risk Score Integration Panel for Alzheimer's 45%
see_also📖CSF and Blood Biomarkers in Progressive Supranuclear Palsy45%
see_also📖Speech and Cognitive Biomarkers for Alzheimer's Disease45%
see_also📖VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers45%
see_also📖BLAAC PD - Black and African Americans Connections to PD (NC45%
see_also📖Clostridium Butyricum for Motor and Non-motor Symptoms in Pa45%
see_also📖CNversyt and Megan Rodden ALS Trials45%
see_also📖Cognitive and Speech Rehabilitation in CBS (NCT05823421)45%
see_also📖First-in-Human 4R Tau Ligand Study in PSP (NCT07348276)45%
see_also📖Gait Analysis Parameter and Upper Limb Evaluation in Neurolo45%
see_also📖Gait and Upper Limb Evaluation in PSP (NCT07136844)45%
see_also📖GBA Brain Molecular Imaging and Blood Biomarkers for Precisi45%
see_also📖Safety and Clinical Outcomes Study: Amniotic and Umbilical C45%
see_also📖A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, M45%
see_also📖A Phase III, Randomized, Double-Blind, Placebo-Controlled, M45%
see_also📖A Multicenter, Phase III, Randomized, Double Blind, Placebo-45%
see_also📖A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C45%
see_also📖A Phase 3, Randomized, Double-blind, Placebo-controlled, Par45%
see_also📖Whole-Body Photobiomodulation for Motor and Cognitive Change45%
see_also📖PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD45%
see_also📖Quality of Life and Caregiver Burden in PSP (NCT03638505)45%
see_also📖Silymarin for Neuroprotection and Symptom Management in Park45%
see_also📖Social Behaviors and Quality of Life in Parkinson's Dis45%
see_also📖Clinical Efficacy and Mechanism of tDCS for Dysphagia in Par45%
see_also📖alexander-disease45%
see_also📖Alexander Disease Genetic Variants45%
see_also📖ATP13A9 and Parkinson's Disease45%
see_also📖Callosal Disconnection and Interhemispheric Dysfunction in C45%
see_also📖Cross-National Cancer-Dementia Correlation and Shared Diseas45%
see_also📖Cancer-Dementia Inverse Correlation: Epidemiological Evidenc45%
see_also📖Caregiver Burden and Support in Corticobasal Syndrome45%
see_also📖Caregiver Support and Palliative Care in Atypical [Parkinson45%
see_also📖Clinical Phenotypes and Subtypes of Corticobasal Syndrome45%
see_also📖Natural History and Prognosis of Corticobasal Syndrome45%
see_also📖Dysphagia and Nutritional Management in Corticobasal Syndrom45%
see_also📖Environmental Toxins and Parkinson's Risk45%
see_also📖HIV-Associated Neurocognitive Disorders (HAND)45%
see_also📖Hemiballismus and Hemichorea in Corticobasal Syndrome45%
see_also📖Investment Landscape: ALS45%
see_also📖Investment Landscape: Frontotemporal Dementia45%
see_also📖Investment Landscape: Huntington's Disease45%
see_also📖Investment Landscape: Parkinson's Disease45%
see_also📖Japanese and German Case Series in Corticobasal Degeneration45%
see_also📖Jervell and Lange-Nielsen Syndrome45%
see_also📖LRRK2 Gene Variants and Mutations45%
see_also📖Nutritional Support and Dietary Interventions in Corticobasa45%
see_also📖Postural Dysfunction and Abnormalities in Corticobasal Syndr45%
see_also📖Pseudobulbar Affect and Emotional Lability in Corticobasal S45%
see_also📖Quality of Life and Caregiver Burden in Progressive Supranuc45%
see_also📖Speech and Voice Disorders in PSP45%
see_also📖Sandhoff Disease45%
see_also📖Sialorrhea and Drooling in Corticobasal Syndrome45%
see_also📖Simultanagnosia and Balint's Syndrome in Corticobasal S45%
see_also📖SNCA Gene Variants and Mutations45%
see_also📖Vocational Rehabilitation and Driving in Corticobasal Syndro45%
see_also📖Voice and Speech in Corticobasal Syndrome45%
see_also📖ABCA7 Lipid Transport and Microglial Phagocytosis AD Causal 45%
see_also📖Shared Mechanisms Between Alzheimer and Parkinson Disease45%
see_also📖ALS Biomarkers and Disease Monitoring45%
see_also📖APOE4 and Alzheimer's Disease Risk45%
see_also📖Blood-Brain Barrier and Neuroimmune Interface in CBS/PSP45%
see_also📖C9orf72 Repeat Expansions in CBS and PSP45%
see_also📖Myoclonus and Cortical Hyperexcitability in Corticobasal Syn45%
see_also📖VEGF and Angiogenesis Dysregulation in CBS/PSP45%
see_also📖Pupillometry and Chromatic Pupillometry in Corticobasal Synd45%
see_also📖FTDP-17 Clinical Phenotypes and Disease Progression45%
see_also📖FTLD-TDP Subtypes and Mechanisms45%
see_also📖GBA Glucocerebrosidase Dysfunction and Parkinson's Dise45%
see_also📖Iron and Neuromelanin Accumulation in PSP45%
see_also📖LRRK2 Kinase Activation and Endolysosomal Dysfunction in Par45%
see_also📖MSA Clinical Features and Diagnosis45%
see_also📖mTOR Signaling in Autophagy and Lysosomal Function45%
see_also📖Neuroresilience Mechanisms and Evidence45%
see_also📖NLRP3 Inhibitors in Parkinson's Disease: Research and C45%
see_also📖Pesticides and Parkinson Disease (Pest-PD) — NCT0642031045%
see_also📖Advanced Proteolysis and Ubiquitin System Targeting in CBS/P45%
see_also📖Gait and Balance Disorders in Progressive Supranuclear Palsy45%
see_also📖HLA Haplotypes and Neuroinflammatory Profiles in PSP45%
see_also📖PSP Liquid-Liquid Phase Separation and Biomolecular Condensa45%
see_also📖PSP Lysosomal Dysfunction and Autophagy Impairment45%
see_also📖Metabolic Dysfunction and Insulin Resistance in Progressive 45%
see_also📖Pupillary and Visual Dysfunction in Progressive Supranuclear45%
see_also📖PSP Tau Propagation and Spreading Mechanisms45%
see_also📖PSP Weight Loss and Cachexia45%
see_also📖Sleep Architecture Changes in CBS and PSP45%
see_also📖Sleep and Circadian Dysfunction in Alzheimer's Disease45%
see_also📖Somatic Mutations and Brain Mosaicism45%
see_also📖Speech and Language Deficits in Corticobasal Syndrome45%
see_also📖Synaptic Loss and Dysfunction Pathway45%
see_also📖TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Chain45%
mentions🔬Senescent cell clearance as neurodegeneration therapy40%
mentions🔬Analyze circuit-level changes in neurodegeneration using All40%
mentions🔬What are the mechanisms underlying perivascular spaces and g40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Perivascular spaces and glymphatic clearance failure in AD40%
mentions🔬What are the mechanisms underlying tdp-43 phase separation t40%
mentions🔬What are the mechanisms underlying blood-brain barrier trans40%
mentions🔬What are the mechanisms underlying senolytic therapy for age40%
mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%
related🧪Ganglioside Rebalancing Therapy40%
related🧪Arginine Methylation Enhancement Therapy40%
related🧪Complement C1q Mimetic Decoy Therapy40%
related🧪CYP46A1 Overexpression Gene Therapy40%
related🧪SIRT6-NAD+ Axis Enhancement Therapy40%
related🧪PARP1 Inhibition Therapy40%
related🧪Hypocretin-Neurogenesis Coupling Therapy40%
related🧪Orexin-Microglia Modulation Therapy40%
related🧪Lysosomal Calcium Channel Modulation Therapy40%
related🧪Circadian Glymphatic Entrainment via Targeted Orexin Recepto40%
related🧪Targeted APOE4-to-APOE3 Base Editing Therapy40%
related🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th40%
related🧪Lysosomal Positioning Dynamics Modulation40%
related🧪Gamma entrainment therapy to restore hippocampal-cortical sy40%
related🧪Glial Glycocalyx Remodeling Therapy40%
related🧪R-Loop Resolution Enhancement Therapy40%
related🧪HCN1-Mediated Resonance Frequency Stabilization Therapy40%
related🧪TET2-Mediated Demethylation Rejuvenation Therapy40%
related🧪Selective Acid Sphingomyelinase Modulation Therapy40%
related🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)40%
related🧪Purinergic P2Y12 Inverse Agonist Therapy40%
related🧪Near-infrared light therapy stimulates COX4-dependent mitoch40%
related🧪Ganglioside Rebalancing Therapy35%
related🧪APOE Isoform Conversion Therapy35%
related🧪Arginine Methylation Enhancement Therapy35%
related🧪Complement C1q Mimetic Decoy Therapy35%
related🧪CYP46A1 Overexpression Gene Therapy35%
related🧪Liquid-Liquid Phase Separation Modifier Therapy35%
related🧪SIRT6-NAD+ Axis Enhancement Therapy35%
related🧪Glymphatic System-Enhanced Antibody Clearance Reversal35%
related🧪PARP1 Inhibition Therapy35%
related🧪Hypocretin-Neurogenesis Coupling Therapy35%
related🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding35%
related🧪Orexin-Microglia Modulation Therapy35%
related🧪Lysosomal Calcium Channel Modulation Therapy35%
related🧪Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy35%
related🧪Circadian Glymphatic Entrainment via Targeted Orexin Recepto35%
related🧪Targeted APOE4-to-APOE3 Base Editing Therapy35%
related🧪Cholesterol-CRISPR Convergence Therapy for Neurodegeneration35%
related🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th35%
related🧪Gamma entrainment therapy to restore hippocampal-cortical sy35%
related🧪Glial Glycocalyx Remodeling Therapy35%
related🧪R-Loop Resolution Enhancement Therapy35%
related🧪APOE4-Selective Lipid Nanoemulsion Therapy35%
related🧪HCN1-Mediated Resonance Frequency Stabilization Therapy35%
related🧪TET2-Mediated Demethylation Rejuvenation Therapy35%
related🧪Selective Acid Sphingomyelinase Modulation Therapy35%
related🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)35%
related🧪Purinergic P2Y12 Inverse Agonist Therapy35%
related🧪Near-infrared light therapy stimulates COX4-dependent mitoch35%
related🔬What are the mechanisms underlying selective vulnerability o30%
SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub